A medical treatment that helps stimulate the recovery of leg motor functions in adults with spinal cord injuries and neurological functions has recently been approved. The treatment could have a profound effect on plaintiffs who have suffered catastrophic injuries in Texas.
The United States Food and Drug Administration recently awarded GTX Medical of Switzerland with a breakthrough device designation for the Go-2 targeted epidural spinal stimulation system. This implantable device improves brain connections with paralyzed muscles in individuals who have a catastrophic injury of the spinal cord.
Clinical trials for the system are slated to take place in 2021. In addition, GTX is developing a wearable, non-invasive electrical spinal stimulation therapy called the LIFT system that previously received breakthrough device designation in 2017 and is expected to undergo conical trials later in 2020. Th Up-LIFT device targets upper limb and hand strength through mild electrical pulses delivered through the skin.
These two devices working in conjunction with one another could make a marked difference in the quality of life for individuals disabled through a catastrophic injury. Both devices have the potential improve functional recovery and increase the independence of individuals living with spinal cord injuries.
The new therapies could have significant implications for plaintiffs seeking compensation for medical treatments related to their injuries. While the plaintiff’s ability to recover may be positively affected by these devices, defense attorneys might try even harder to show that the plaintiff was at least partially at fault to reduce the amount of the award for medical treatment, mental pain and suffering and other damages. Patients may need to work closely with their attorneys to ensure that they get the best possible settlement outcome to compensate for loss of income as well as for proper medical treatment.